Trial Profile
A trial comparing efficacy and safety of photodynamic therapy using reduced irradiation time or reduced verteporfin dose in patients with chronic central serous chorioretinopathy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2016
Price :
$35
*
At a glance
- Drugs Verteporfin (Primary)
- Indications Central serous chorioretinopathy
- Focus Therapeutic Use
- 28 Jun 2016 New trial record